Unichem Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Unichem Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹63 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹65 tied up three years earlier. More money tied up than 97% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 66% in 3 years; of every extra ₹100 of sales, ₹53 became extra profit. Higher than 95% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹4 of operating cash. Lower than 93% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹4Over the last 3 years, every ₹100 of reported profit came with ₹4 of operating cash.
Lower than 93% of Healthcare companies in India.
Self-Funding Ratio
0.0×Over the last 3 years its own operating cash paid for 4% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 89% of Healthcare companies in India.
Cash Locked Ratio
₹63For every ₹100 of sales, ₹63 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹65 tied up three years earlier.
More money tied up than 97% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹53Sales grew 66% in 3 years; of every extra ₹100 of sales, ₹53 became extra profit.
Higher than 95% of Healthcare companies in India.
Asset Productivity Ratio
+66% / +17%In 3 years sales changed by +66% while total assets changed by +17%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.0×Debt due within a year is covered 0.0 times by its yearly operating cash.
Lower than 88% of Healthcare companies in India.
Cash Cushion Ratio
−6%Debt, after subtracting cash, equals 6% of its market value (net debt).
Lower than 70% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 73% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 74% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Unichem Laboratories Limited owes ₹0.27 for every ₹1 it owns. Net profit rose 84% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
11.3Investors pay ₹11.3 for every ₹1 of Unichem Laboratories Limited's yearly profit, lower than 95% of Healthcare companies in India.
P/B ratio
1.26The share price is 1.26 times Unichem Laboratories Limited's book value per share, lower than 96% of Healthcare companies in India.
Market cap
₹3,434 CrThe total market value of all of Unichem Laboratories Limited's shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹2,717 CrWhat Unichem Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹385.97Net worth divided by the number of shares. The share price of ₹487.75 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
11.2%Unichem Laboratories Limited earned 11.2% on its shareholders' money over the last year, lower than 59% of Healthcare companies in India.
Owes vs Owns
0.27×Unichem Laboratories Limited owes ₹0.27 for every ₹1 it owns (low), lower than 70% of Healthcare companies in India.
Dividend yield
NoneUnichem Laboratories Limited does not currently pay a dividend.
Revenue growth
+5%Revenue rose 5% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Profit growth
+84%Net profit rose 84% in the year to Mar 2026.
Profit margin
11.7%Unichem Laboratories Limited keeps ₹12 of every ₹100 of revenue as net profit.
Cash quality
0.0×Cash from Unichem Laboratories Limited's business was 0.0× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
2.0×Unichem Laboratories Limited's operating profit covered its interest costs 2.0 times in the year to Mar 2026.
Cash vs debt
Net debtUnichem Laboratories Limited had ₹211 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Unichem Laboratories Limited's P/E ratio?
Investors pay ₹11.3 for every ₹1 of Unichem Laboratories Limited's yearly profit, lower than 95% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Unichem Laboratories Limited: ₹3,434 Cr ÷ ₹2,717 Cr (31 Mar 2026) = 1.3.
What is Unichem Laboratories Limited's return on equity?
Unichem Laboratories Limited earned 11.2% on its shareholders' money over the last year, lower than 59% of Healthcare companies in India.
How much does Unichem Laboratories Limited owe compared with what it owns?
Unichem Laboratories Limited owes ₹0.27 for every ₹1 it owns (low), lower than 70% of Healthcare companies in India.
Does Unichem Laboratories Limited pay a dividend?
No. Unichem Laboratories Limited does not currently pay a dividend.
Is Unichem Laboratories Limited's revenue growing?
Revenue rose 5% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.